BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Ascletis Reports 44.8% Weight Reduction in Obese Mouse Model with Combination of ASC47 and Novel Dual GLP-1R/GIPR Agonist ASC31

Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), ...

August 19, 2025 | News

Novo Nordisk Expands U.S. Access to FDA-Approved Ozempic® with $499 Monthly Offer for Uninsured Patients

Offer supports access for eligible patients without insurance to FDA-approved Ozempic® (semaglutide) injection 0.5 mg, 1 mg,...

August 19, 2025 | News

Superluminal Medicines and Eli Lilly Forge $1.3 Billion Collaboration on Undisclosed GPCR Targets in Cardiometabolic Disease and Obesity

Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as...

August 15, 2025 | News

Innovent Biologics gets FDA nod to begin Phase 1 trials of oral GLP-1R agonist IBI3032

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

August 05, 2025 | News

Fangzhou and Novo Nordisk Forge Strategic Alliance to Revolutionise Chronic Disease Management with AI

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, ...

July 21, 2025 | News

Ascletis Completes Dosing in U.S. Trial of ASC47 and Semaglutide for Obesity

The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day ...

July 15, 2025 | News

Amarna Therapeutics and NorthX Biologics Advance Nimvec™ AM510 Toward Clinical Trials for Type 1 Diabetes

Fast-Tracking Clinical Readiness: The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 ...

July 14, 2025 | News

Silo Pharma and Hoth Therapeutics to Jointly Develop VA-Invented Biologic for Obesity and Metabolic Disorders

Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therap...

June 26, 2025 | News

Eluminex Reports Positive Phase 1 Results for EB-105 in Diabetic Macular Edema Patients

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels No Safety Issues Observed...

June 10, 2025 | News

Zuellig Pharma to Launch Eli Lilly’s Mounjaro® in Thailand to Address Growing Obesity and Diabetes Burden

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes me...

May 27, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Singapore’s NUS Researchers Develop Dual Microneedle Technologies to Accelerate Healing of Diabetic Wounds

Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by persistent inflammati...

March 27, 2025 | News

MicuRx’s MRX-4 and Contezolid Show Favorable Safety and Efficacy in Phase III Trial for Diabetic Foot Infections

Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued pro...

February 26, 2025 | News

BioMed X Launches Research Hub in Barbados to Advance Cardiometabolic Disease Treatment for Individuals of African Descent

BioMed X Institute, in collaboration with the Government of Barbados and the European Commission, is launching BioMed X Barbados, a new rese...

February 21, 2025 | News

Stay Connected